Use of continuous glucose monitor as a motivational device for lifestyle modifications to improve glycaemic control in patients with type 2 diabetes treated with non-insulin therapies

Farhan, Hisham; Bukhari, Khulood; Grewal, Navneet; Devarasetty, Sranita; Munir, Kashif M.

doi:10.1136/bcr-2021-248579

Cited by 6 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…diabetes tipo 1 y tipo 2, ha demostrado ser una herramienta fundamental para la educación del paciente y la adherencia a los cambios en estilo de vida (7,8). En mujeres embarazadas, ha mejorado los desenlaces maternos y neonatales (9).…”

Section: Introductionunclassified

Interpretación del monitoreo continuo de glucosa: una visión práctica

Coronel-Restrepo¹,

Rincón²,

Palacio³

et al. 2023

Rev.ACE

View full text Add to dashboard Cite

Contexto: las herramientas para el monitoreo de glucosa a nivel capilar, como intersticial, han evolucionado en precisión y exactitud. Puntualmente, los sistemas de monitoreo continuo de glucosa han permitido alcanzar las metas de control en pacientes con diabetes de una manera más fácil. Aunque la literatura médica recomienda que la información obtenida de estos dispositivos debe estar organizada y resumida, el proceso estructurado de interpretación no está estandarizado. Objetivo: describir desde una perspectiva práctica, sencilla e intuitiva, la interpretación de los datos del sistema de monitoreo continuo de glucosa. Metodología: se realizó una búsqueda descriptiva de la literatura en la base de datos PubMed y se seleccionaron artículos pertinentes a los objetivos propuestos. A través de reuniones periódicas presenciales y virtuales, se diseñó un esquema de interpretación de los registros de monitorización continua de glucosa, teniendo en cuenta las recomendaciones de la literatura y la experiencia personal de los autores para llegar a un consenso práctico. Resultados: los objetivos de interpretación se resumieron en 4 pasos: 1) Determinar si el estudio es confiable; 2) Definir el problema; 3) Determinar dónde está el problema; 4) identificar la etiología del problema. Conclusiones: la interpretación de la información de los sistemas de monitoreo continuo de glucosa deben de ser sencillas, intuitivas y prácticas.

show abstract

Section: Introductionunclassified

Interpretación del monitoreo continuo de glucosa: una visión práctica

Coronel-Restrepo¹,

Rincón²,

Palacio³

et al. 2023

Rev.ACE

View full text Add to dashboard Cite

show abstract

Reduction in Diabetes-Related Hospitalizations and Medical Costs After Dexcom G6 Continuous Glucose Monitor Initiation in People with Type 2 Diabetes Using Intensive Insulin Therapy

Hannah,

Nemlekar,

Green

et al. 2024

Adv Ther

View full text Add to dashboard Cite

Introduction Some people with type 2 diabetes (T2D) require intensive insulin therapy to manage their diabetes. This can increase the risk of diabetes-related hospitalizations. We hypothesize that initiation of real-time continuous glucose monitoring (RT-CGM), which continuously measures a user’s glucose values and provides threshold- and trend-based alerts, will reduce diabetes-related emergency department (ED) and inpatient hospitalizations and concomitant costs. Methods A retrospective analysis of US healthcare claims data using Optum’s de-identified Clinformatics ® Data Mart database was performed. The cohort consisted of commercially insured, CGM-naïve individuals with T2D who initiated Dexcom G6 RT-CGM system between August 1, 2018, and March 31, 2021. Twelve months of continuous health plan enrollment before and after RT-CGM initiation was required to capture baseline and follow-up rates of diabetes-related hospitalizations and associated healthcare resource utilization (HCRU) costs. Analyses were performed for claims with a diabetes-related diagnosis code in either (1) any position or (2) first or second position on the claim. Results A total of 790 individuals met the inclusion criteria. The average age was 52.8 (10.5) [mean (SD)], 53.3% were male, and 76.3% were white. For claims with a diabetes-related diagnosis code in any position, the number of individuals with ≥ 1 ED visit decreased by 30.0% ( p = 0.01) and with ≥ 1 inpatient visit decreased by 41.5% ( p < 0.0001). The number of diabetes-related visits and average number of visits per person similarly decreased by at least 31.4%. Larger relative decreases were observed for claims with a diabetes-related diagnosis code in the first or second position on the claim. Total diabetes-related costs expressed as per-person-per-month (PPPM) decreased by $341 PPPM for any position and $330 PPPM for first or second position. Conclusion Initiation of Dexcom G6 among people with T2D using intensive insulin therapy was associated with a significant reduction in diabetes-related ED and inpatient visits and related HCRU costs. Expanded use of RT-CGM could augment these benefits and result in further cost reductions. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-024-02851-8.

show abstract